The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2-negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naïve advanced gastric cancer: A pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
 
Jin Matsuyama
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai/Roche; Chugai/Roche; Chugai/Roche; Chugai/Roche; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD K.K; MSD K.K; MSD K.K; MSD K.K; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst)
 
Kazumasa Fujitani
No Relationships to Disclose
 
Yusuke Akamaru
No Relationships to Disclose
 
Shigeyuki Tamura
No Relationships to Disclose
 
Shunji Endo
No Relationships to Disclose
 
Yutaka Kimura
No Relationships to Disclose
 
Youichi Makari
No Relationships to Disclose
 
Takao Tamura
Honoraria - Merck Serono; Merck Serono; Merck Serono; Merck Serono
Speakers' Bureau - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Naotoshi Sugimoto
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Toshimasa Tsujinaka
No Relationships to Disclose
 
Masahiro Goto
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Yukinori Kurokawa
Honoraria - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Medtronic; Medtronic; Medtronic; Medtronic; MSD; MSD; MSD; MSD; Olympus; Olympus; Olympus; Olympus; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Stryker; Stryker; Stryker; Stryker; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Toshio Shimokawa
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nihonkayaku; Nihonkayaku; Nihonkayaku; Nihonkayaku; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nihonkayaku; Nihonkayaku; Nihonkayaku; Nihonkayaku; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Takara Bio; Takara Bio; Takara Bio; Takara Bio
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)